Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC)

Trial Profile

Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Semagacestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IDENTITY-XT
  • Sponsors Eli Lilly
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Aug 2011 Status changed from active, no longer recruiting to completed.
    • 17 Dec 2010 Primary endpoint changed from difference in vital signs to changes from baseline in Alzheimer's Disease Assessment Scale - Cognitive subscale and Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory in ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top